Barry Kappel, Sapience Therapeutics CEO
Peptide biotech gets renewed support from Bristol Myers, others to bankroll multiple oncology clinical programs
The first batch of financing lasted about five years, but this time around, Sapience Therapeutics thinks its new funding round will have runway for less …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.